Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sad448. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 1/20 | 1.00 |
| ▸ | CNR2 known ✓ | P34972 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.31 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844333 | 0.95 | CNR1 (0.90) | CNR1CNR2PIK3CDPKMYT1 | |
| SCHEMBL17692331 | 0.95 | CNR1 (0.90) | CNR1CNR2KDM4ETHRBADORA1 | |
| SCHEMBL844174 | 0.93 | CNR1 (0.87) | CNR1CNR2KDM4ETHRBADORA1 | |
| Hydrochloric Acid SCHEMBL844735 | 0.92 | CNR1 (0.86) | CNR1CNR2KDM4ETHRBADORA1 | |
| SCHEMBL17692388 | 0.92 | CNR1 (0.86) | CNR1CNR2KDM4EPIK3CDPKMYT1 | |
| SCHEMBL845014 | 0.89 | CNR1 (0.80) | CNR1CNR2KDM4EPIK3CDPKMYT1 | |
| SCHEMBL844571 | 0.88 | CNR1 (0.79) | CNR1CNR2KDM4ETHRBADORA1 | |
| SCHEMBL17694535 | 0.88 | CNR1 (0.79) | CNR1CNR2KDM4ETHRBADORA1 | |
| SCHEMBL18673206 | 0.88 | CNR1 (0.78) | CNR1CNR2KDM4EPIK3CDALDH1A1 | |
| SCHEMBL17692387 | 0.87 | CNR1 (0.77) | CNR1CNR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552015-B2 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | claimed |
| EP-1472234-B1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | claimed |
| EP-2319839-A1 | Quinazolinone derivatives and their use as CB agonists | Novartis AG (CH) | 2011-05-11 | — | — | EP | claimed |
| US-20080004296-A1 | Organic Compounds | CHARMAN CHRISTINE | 2008-01-03 | — | — | US | claimed |
| US-20070265285-A1 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | claimed |
| WO-2005123694-A2 | QUINAZOLINONE COMPOUNDS FOR THE TREATMENT OF COUGH | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | claimed |
| WO-2005058326-A1 | USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs) | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | claimed |
| US-20050085493-A1 | Quinazolinone derivatives and their use as cb agonists | BRAIN CHRISTOPHER T (GB) | 2005-04-21 | — | — | US | claimed |
| EP-1472234-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | Novartis AG (CH) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066603-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | claimed |
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9604949-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-8552015-B2 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| WO-2005123694-A2 | QUINAZOLINONE COMPOUNDS FOR THE TREATMENT OF COUGH | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005058326-A1 | USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs) | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050085493-A1 | Quinazolinone derivatives and their use as cb agonists | BRAIN CHRISTOPHER T (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1472234-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | Novartis AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066603-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885KDM4E 4090/4885 |
| US-20070265285-A1 | Quinazolinone derivatives and their use as CB agonists | CNR1, ADRB1, ADRA1D | CNR1 1/4885CNR2 8/4885KDM4E 3258/4885 |
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885KDM4E 4090/4885 |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885KDM4E 4090/4885 |
| US-20080004296-A1 | Organic Compounds | OTC, OAT, CHRM1 | CNR1 595/4885CNR2 1208/4885KDM4E 3309/4885 |
| US-20050085493-A1 | Quinazolinone derivatives and their use as cb agonists | CNR1, ADRB1, ADRA2B | CNR1 1/4885CNR2 8/4885KDM4E 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.